Literature DB >> 34278937

Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study.

Samer Al Hadidi1,2,3,4,5, Deepa Dongarwar3, Hamisu M Salihu3, Rammurti T Kamble1,2,4, Premal Lulla1,2,4, LaQuisa C Hill1,2,4, George Carrum1,2,4, Carlos A Ramos1,2,4, Helen E Heslop1,2,4, Saad Z Usmani6.   

Abstract

Hispanics and non-Hispanic (NH)-Blacks continue to face numerous health disparities related to multiple myeloma (MM). We aimed to analyze trends of MM-related hospitalizations and incidence of in-hospital mortality with a 10-year cross-sectional analysis of inpatient hospitalizations. The prevalence of MM-related hospitalizations was higher in NH-Blacks compared to NH-Whites (476.0 vs. 305.6 per 100,000 hospitalizations, p < .001). MM-related in-hospital mortality was higher in Hispanics compared to NH-Whites and NH-Blacks (6.2 vs. 5.3%, p < .001). Using average annual percent change (AAPC), we found a statistically significant decline of in-hospital mortality among all MM patients except NH-Blacks (AAPC: -2.2, 95% confidence interval (CI) -4.7, 0.4, p = .47), who had the highest inpatient mortality in recent years. Multivariate analysis showed that NH-Blacks received fewer transplants, more blood product transfusions, fewer palliative care consults, less inpatient chemotherapy, and utilized more intensive care. Disparities in MM care for NH-Blacks and Hispanics continue to persist despite recent advancements in MM therapy.

Entities:  

Keywords:  African Americans; Black Americans; Hispanics; Multiple myeloma; disparities; health disparities

Mesh:

Year:  2021        PMID: 34278937      PMCID: PMC8962656          DOI: 10.1080/10428194.2021.1953013

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

1.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

2.  With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.

Authors:  Nathanael R Fillmore; Sarvari V Yellapragada; Chizoba Ifeorah; Ansh Mehta; Diana Cirstea; Paul S White; Gustavo Rivero; Andrew Zimolzak; Saiju Pyarajan; Nhan Do; Mary Brophy; Nikhil C Munshi
Journal:  Blood       Date:  2019-04-19       Impact factor: 22.113

3.  Is Early Palliative Care Feasible in Patients With Multiple Myeloma?

Authors:  Josep Porta-Sales; Maria Guerrero-Torrelles; Deborah Moreno-Alonso; Josep Sarrà-Escarré; Victòria Clapés-Puig; Jordi Trelis-Navarro; Anna Sureda-Balarí; Alberto Fernández De Sevilla-Ribosa
Journal:  J Pain Symptom Manage       Date:  2017-08-12       Impact factor: 3.612

4.  Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications.

Authors:  E Dianne Pulte; Lei Nie; Nicole Gormley; Kirsten B Goldberg; Amy McKee; Ann Farrell; Richard Pazdur
Journal:  Blood Adv       Date:  2018-01-23

5.  Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.

Authors:  Sikander Ailawadhi; Kejal Parikh; Safiya Abouzaid; Zhou Zhou; Wenxi Tang; Zoe Clancy; Claudia Cheung; Zheng-Yi Zhou; Jipan Xie
Journal:  Blood Adv       Date:  2019-10-22

6.  Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases.

Authors:  Zarko Manojlovic; Austin Christofferson; Winnie S Liang; Jessica Aldrich; Megan Washington; Shukmei Wong; Daniel Rohrer; Scott Jewell; Rick A Kittles; Mary Derome; Daniel Auclair; David Wesley Craig; Jonathan Keats; John D Carpten
Journal:  PLoS Genet       Date:  2017-11-22       Impact factor: 5.917

7.  Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs.

Authors:  Samer Al Hadidi; Martha Mims; Courtney Nicole Miller-Chism; Rammurti Kamble
Journal:  Ann Intern Med       Date:  2020-06-23       Impact factor: 25.391

8.  Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.

Authors:  Sikander Ailawadhi; Ryan D Frank; Pooja Advani; Abhisek Swaika; M'hamed Temkit; Richa Menghani; Mayank Sharma; Zahara Meghji; Shumail Paulus; Nandita Khera; Shahrukh K Hashmi; Aneel Paulus; Tanya S Kakar; David O Hodge; Dorin T Colibaseanu; Michael R Vizzini; Vivek Roy; Gerardo Colon-Otero; Asher A Chanan-Khan
Journal:  Cancer Med       Date:  2017-11-03       Impact factor: 4.452

9.  Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry.

Authors:  Linda B Baughn; Kathryn Pearce; Dirk Larson; Mei-Yin Polley; Eran Elhaik; Michael Baird; Colin Colby; Joanne Benson; Zhuo Li; Yan Asmann; Terry Therneau; James R Cerhan; Celine M Vachon; A Keith Stewart; P Leif Bergsagel; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar
Journal:  Blood Cancer J       Date:  2018-10-10       Impact factor: 11.037

Review 10.  Multiple myeloma current treatment algorithms.

Authors:  S Vincent Rajkumar; Shaji Kumar
Journal:  Blood Cancer J       Date:  2020-09-28       Impact factor: 11.037

View more
  2 in total

1.  Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.

Authors:  Samer Al Hadidi; Carolina Schinke; Sharmilan Thanendrarajan; Maurizio Zangari; Frits van Rhee
Journal:  JAMA Netw Open       Date:  2022-04-01

2.  Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.

Authors:  Raghad Alqazaqi; Carolina Schinke; Sharmilan Thanendrarajan; Maurizio Zangari; John Shaughnessy; Fenghuang Zhan; Guido Tricot; Frits van Rhee; Samer Al Hadidi
Journal:  JAMA Netw Open       Date:  2022-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.